2022
NIMG-07. APPLYING A GLIOMA-TRAINED DEEP LEARNING AUTO-SEGMENTATION TOOL ON BM PRE- AND POST-RADIOSURGERY
Kaur M, Varghese S, Jekel L, Tillmanns N, Merkaj S, Bousabarah K, Lin M, Bhawnani J, Chiang V, Aboian M. NIMG-07. APPLYING A GLIOMA-TRAINED DEEP LEARNING AUTO-SEGMENTATION TOOL ON BM PRE- AND POST-RADIOSURGERY. Neuro-Oncology 2022, 24: vii162-vii163. PMCID: PMC9660643, DOI: 10.1093/neuonc/noac209.626.Peer-Reviewed Original ResearchStereotactic radiosurgeryPosttreatment lesionsBoard-certified neuroradiologistsRoutine clinical useWhole tumorTumor coreMulticentric lesionsTreatment responsePeritumoral edemaBM preLesionsClinical useVolumetric segmentationEdemaPatientsT2w FLAIRTherapy planningTumorsDedicated trainingLesion detectionBM dataVolumetric measurementsBMMRIPre
2021
Deep learning–assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver
Oestmann PM, Wang CJ, Savic LJ, Hamm CA, Stark S, Schobert I, Gebauer B, Schlachter T, Lin M, Weinreb JC, Batra R, Mulligan D, Zhang X, Duncan JS, Chapiro J. Deep learning–assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver. European Radiology 2021, 31: 4981-4990. PMID: 33409782, PMCID: PMC8222094, DOI: 10.1007/s00330-020-07559-1.Peer-Reviewed Original ResearchConceptsNon-HCC lesionsHepatocellular carcinomaHCC lesionsAtypical imagingGrading systemLI-RADS criteriaAtypical imaging featuresPrimary liver cancerTypical hepatocellular carcinomaAtypical hepatocellular carcinomaContrast-enhanced MRISensitivity/specificityLiver transplantMethodsThis IRBRetrospective studyLiver malignanciesImaging featuresLiver cancerAtypical featuresConclusionThis studyLesionsMRIClinical applicationCarcinomaImage-based diagnosis
2014
Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI
Chapiro J, Lin M, Duran R, Schernthaner RE, Geschwind JF. Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI. Expert Review Of Anticancer Therapy 2014, 15: 199-205. PMID: 25371052, PMCID: PMC4304995, DOI: 10.1586/14737140.2015.978861.Peer-Reviewed Original ResearchConceptsTumor responseResponse Evaluation CriteriaTumor response criteriaMajor clinical interestLiver cancer therapyLiver cancer lesionsClinical evidenceIntraarterial therapyCancer lesionsSolid tumorsResponse criteriaAnatomic methodsClinical interestImaging modalitiesCancer therapyTumor analysisTherapyMRILesionsTumors